{"id":"aflibercept-and-ranibizumab","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Conjunctival hemorrhage"},{"rate":"5-15","effect":"Eye pain"},{"rate":"5-10","effect":"Floaters"},{"rate":"5-10","effect":"Intraocular pressure elevation"},{"rate":"0.1-0.5","effect":"Endophthalmitis"},{"rate":"0.1-1","effect":"Retinal detachment"}]},"_chembl":{"chemblId":"CHEMBL1201825","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept is a recombinant fusion protein that acts as a VEGF trap, binding and sequestering VEGF-A and VEGF-B. Ranibizumab is a monoclonal antibody fragment that directly binds and neutralizes VEGF-A. Both agents prevent VEGF-mediated angiogenesis and vascular permeability, reducing pathological neovascularization and edema in retinal diseases.","oneSentence":"Aflibercept and ranibizumab are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:16.427Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration (wet/neovascular)"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT06985706","phase":"PHASE3","title":"Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns","status":"RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2025-05-19","conditions":"Severe Diabetic Macular Oedema","enrollment":264},{"nctId":"NCT03832179","phase":"PHASE4","title":"Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification","status":"COMPLETED","sponsor":"Bay Area Retina Associates","startDate":"2018-11-15","conditions":"Diabetic Macular Edema, Cataract","enrollment":16},{"nctId":"NCT07009574","phase":"","title":"The Treatment Burden of Myopic Choroidal Neovascularization","status":"NOT_YET_RECRUITING","sponsor":"Policlinico Gaspare Rodolico - San Marco Catania","startDate":"2025-06-01","conditions":"Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden","enrollment":100},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT02397954","phase":"PHASE2","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2015-03-12","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":4},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT05640895","phase":"","title":"Intravitreal Injection Site and Perceived Pain","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2022-11-14","conditions":"Pain","enrollment":53},{"nctId":"NCT02669953","phase":"","title":"Aflibercept in Recurrent or Persistent CNV","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2015-12","conditions":"Age Related Macular Degeneration, Intravitreal Injections, Diabetic Macular Edema","enrollment":80},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT03709745","phase":"PHASE4","title":"Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"St. Erik Eye Hospital","startDate":"2018-10-18","conditions":"Branch Retinal Vein Occlusion with Macular Edema","enrollment":110},{"nctId":"NCT03630315","phase":"PHASE1","title":"CLN-0046: Treatment of AMD Subjects With OTX-TKI","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2019-02-18","conditions":"Neovascular Age-related Macular Degeneration","enrollment":29},{"nctId":"NCT04662944","phase":"","title":"A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-23","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":494},{"nctId":"NCT05211804","phase":"","title":"Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse","status":"COMPLETED","sponsor":"Sorlandet Hospital HF","startDate":"2022-02-08","conditions":"Wet Macular Degeneration","enrollment":31},{"nctId":"NCT02214628","phase":"PHASE2","title":"Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-07","conditions":"Age-related Macular Degeneration","enrollment":101},{"nctId":"NCT06231121","phase":"","title":"Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2023-12-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":13},{"nctId":"NCT05126966","phase":"PHASE3","title":"A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2023-12-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT06205979","phase":"EARLY_PHASE1","title":"Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-12-12","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT02559180","phase":"PHASE4","title":"Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab","status":"COMPLETED","sponsor":"Rishi Singh","startDate":"2015-10","conditions":"Diabetic Retinopathy, Macular Edema","enrollment":20},{"nctId":"NCT02157077","phase":"PHASE3","title":"Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2013-12","conditions":"Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration","enrollment":90},{"nctId":"NCT04698850","phase":"PHASE4","title":"Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation","status":"WITHDRAWN","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2021-01-04","conditions":"Wet Macular Degeneration","enrollment":""},{"nctId":"NCT05282420","phase":"PHASE4","title":"Ranibizumab Versus Aflibercept for CRVO in Young Patients.","status":"UNKNOWN","sponsor":"South Valley University","startDate":"2021-02-01","conditions":"Non-Ischemic Central Retinal Vein Occlusion With Macular Edema","enrollment":40},{"nctId":"NCT02348359","phase":"PHASE2","title":"X-82 to Treat Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Tyrogenex","startDate":"2015-03-16","conditions":"Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration","enrollment":157},{"nctId":"NCT05222633","phase":"","title":"Anti-VEGF in Real-world","status":"UNKNOWN","sponsor":"Wenbin Wei","startDate":"2022-01-01","conditions":"Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane","enrollment":1000},{"nctId":"NCT05186155","phase":"","title":"Analysis of Ocular and Neurodevelopmental Function for Retinopathy of Prematurity","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-01-01","conditions":"Retinopathy of Prematurity, Neurodevelopmental Abnormality","enrollment":510},{"nctId":"NCT05110209","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":331541},{"nctId":"NCT05146687","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":369600},{"nctId":"NCT02174211","phase":"NA","title":"A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-06","conditions":"Age Related Macular Degeneration","enrollment":59},{"nctId":"NCT04836143","phase":"","title":"Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion","status":"COMPLETED","sponsor":"Kim's Eye Hospital","startDate":"2019-08-26","conditions":"Age-related Macular Degeneration","enrollment":512},{"nctId":"NCT04245072","phase":"NA","title":"Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis","status":"UNKNOWN","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2018-03-27","conditions":"Chorioretinitis","enrollment":100},{"nctId":"NCT02274259","phase":"PHASE4","title":"Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen","status":"COMPLETED","sponsor":"Anders Kvanta","startDate":"2014-10","conditions":"Central Retinal Vein Occlusion","enrollment":40},{"nctId":"NCT03423823","phase":"PHASE2","title":"Ziv-aflibercept Efficacy in Better Regulating AMD","status":"COMPLETED","sponsor":"Kapil Kapoor","startDate":"2017-07-07","conditions":"Wet Macular Degeneration, Wet Age-related Macular Degeneration","enrollment":62},{"nctId":"NCT01627249","phase":"PHASE3","title":"Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2012-08","conditions":"Diabetic Macular Edema","enrollment":660},{"nctId":"NCT04087746","phase":"PHASE4","title":"Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Minia University","startDate":"2017-01","conditions":"Diabetic Macular Edema","enrollment":400},{"nctId":"NCT02457975","phase":"EARLY_PHASE1","title":"Photobiomodulation for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-06","conditions":"Diabetic Retinopathy","enrollment":16},{"nctId":"NCT04018833","phase":"","title":"Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bernardete Pessoa MD","startDate":"2012-01-01","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":40},{"nctId":"NCT03999125","phase":"PHASE4","title":"Anti-VEGF Therapy Versus Dexamethasone Implant for DME","status":"UNKNOWN","sponsor":"Sudhalkar Eye Hospital","startDate":"2019-06-25","conditions":"Clinically Significant Macular Edema Due to Diabetes Mellitus","enrollment":150},{"nctId":"NCT02130024","phase":"PHASE4","title":"A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04-11","conditions":"Age-Related Macular Degeneration","enrollment":281},{"nctId":"NCT03975088","phase":"NA","title":"Sub-macular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema","status":"COMPLETED","sponsor":"University of Alexandria","startDate":"2017-01-01","conditions":"Diabetic Macular Edema","enrollment":19},{"nctId":"NCT03340610","phase":"PHASE4","title":"IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab","status":"COMPLETED","sponsor":"Southeast Retina Center, Georgia","startDate":"2015-06","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT02257632","phase":"PHASE4","title":"Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04-08","conditions":"Wet Age-Related Macular Degeneration","enrollment":41},{"nctId":"NCT02363621","phase":"PHASE2","title":"Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME","status":"COMPLETED","sponsor":"Arshad Khanani","startDate":"2015-01","conditions":"Diabetic Macular Edema","enrollment":101},{"nctId":"NCT01918371","phase":"","title":"A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-08-02","conditions":"Retinal Vein Occlusion, Macular Edema","enrollment":323},{"nctId":"NCT01958918","phase":"PHASE4","title":"Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10-23","conditions":"Neovascular Age-related Macular Degeneration","enrollment":712},{"nctId":"NCT02471651","phase":"PHASE4","title":"Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema","status":"COMPLETED","sponsor":"California Retina Consultants","startDate":"2015-06","conditions":"Diabetic Macular Edema","enrollment":40},{"nctId":"NCT02161575","phase":"PHASE4","title":"Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-28","conditions":"Neovascular Age-related Macular Degeneration","enrollment":103},{"nctId":"NCT01972763","phase":"PHASE1, PHASE2","title":"Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.","status":"COMPLETED","sponsor":"Northern California Retina Vitreous Associates","startDate":"2013-10","conditions":"Recalcitrant Wet Age-related Macular Degeneration","enrollment":12},{"nctId":"NCT02309281","phase":"PHASE4","title":"Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab","status":"COMPLETED","sponsor":"Vista Klinik","startDate":"2013-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":33},{"nctId":"NCT02218177","phase":"","title":"Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-08","conditions":"Age Related Macular Degeneration","enrollment":30},{"nctId":"NCT02591914","phase":"PHASE1","title":"An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Retinal Consultants of Arizona","startDate":"2014-02","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":30},{"nctId":"NCT01617148","phase":"PHASE4","title":"Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept","status":"COMPLETED","sponsor":"Rishi Singh","startDate":"2012-06","conditions":"Exudative Macular Degeneration","enrollment":26},{"nctId":"NCT03324542","phase":"","title":"Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2017-04-03","conditions":"AMD","enrollment":63},{"nctId":"NCT02321241","phase":"","title":"Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-01","conditions":"Wet Macular Degeneration","enrollment":236},{"nctId":"NCT03059277","phase":"PHASE4","title":"Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab","status":"WITHDRAWN","sponsor":"Southeast Clinical Research Associates, LLC","startDate":"2018-06-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT01712035","phase":"","title":"Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2012-10","conditions":"Neovascular Age-related Macular Degeneration","enrollment":44},{"nctId":"NCT02321267","phase":"PHASE4","title":"Cohort Study of the Clinical Course of Macular Diseases in Kagawa","status":"UNKNOWN","sponsor":"Kagawa University","startDate":"2014-12","conditions":"Macular Disease","enrollment":1000},{"nctId":"NCT02291887","phase":"","title":"Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept","status":"COMPLETED","sponsor":"Associated Retinal Consultants, Michigan","startDate":"2014-12-22","conditions":"Age-Related Macular Degeneration","enrollment":13},{"nctId":"NCT03038048","phase":"NA","title":"30g vs 33g Needle for Intravitreal Injections","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2017-01-27","conditions":"Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":50},{"nctId":"NCT01988662","phase":"PHASE4","title":"UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Neovacular Age-related Macular Degeneration","enrollment":205},{"nctId":"NCT02878681","phase":"PHASE4","title":"24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2016-09","conditions":"Visual Impairment Due to Diabetic Macular Edema","enrollment":""},{"nctId":"NCT02634970","phase":"PHASE4","title":"CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2016-03","conditions":"Wet Age-related Macular Degeneration (Wet AMD)","enrollment":""},{"nctId":"NCT01543568","phase":"PHASE4","title":"Study for Recalcitrant Age Related Macular Degeneration","status":"COMPLETED","sponsor":"David M. Brown, M.D.","startDate":"2012-02","conditions":"Age Related Macular Degeneration","enrollment":46},{"nctId":"NCT02258009","phase":"PHASE4","title":"Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-10","conditions":"Visual Impairment Due to Diabetic Macular Edema","enrollment":""},{"nctId":"NCT01414153","phase":"PHASE2","title":"Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD","status":"COMPLETED","sponsor":"Lpath, Inc.","startDate":"2012-08","conditions":"Exudative Age-related Macular Degeneration","enrollment":158},{"nctId":"NCT02081339","phase":"","title":"Cohort Study of the Clinical Course of Macular Diseases in Japanese","status":"UNKNOWN","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2014-03","conditions":"Macular Disease","enrollment":1000},{"nctId":"NCT01942213","phase":"","title":"Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.","status":"COMPLETED","sponsor":"Prism Vision Group","startDate":"2013-12","conditions":"Neovascular Age Related Macular Degeneration","enrollment":136},{"nctId":"NCT02118831","phase":"PHASE1, PHASE2","title":"Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF","status":"COMPLETED","sponsor":"California Retina Consultants","startDate":"2012-03","conditions":"Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":56},{"nctId":"NCT01926977","phase":"PHASE1, PHASE2","title":"Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration","status":"COMPLETED","sponsor":"Arshad Khanani","startDate":"2013-09","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":100},{"nctId":"NCT02651168","phase":"PHASE4","title":"Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2016-03","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT02646670","phase":"PHASE4","title":"Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Instituto de Olhos de Goiania","startDate":"2015-07","conditions":"Retinal Diseases","enrollment":20},{"nctId":"NCT02641457","phase":"PHASE3","title":"Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis","status":"COMPLETED","sponsor":"Instituto de Olhos de Goiania","startDate":"2014-03","conditions":"Glaucoma, Rubeosis Iridis","enrollment":2},{"nctId":"NCT02296567","phase":"PHASE2, PHASE3","title":"Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients","status":"UNKNOWN","sponsor":"East Florida Eye Institute","startDate":"2014-12","conditions":"Age Related Macular Degeneration","enrollment":80},{"nctId":"NCT00637377","phase":"PHASE3","title":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Macular Degeneration","enrollment":1240},{"nctId":"NCT02000102","phase":"","title":"Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-09","conditions":"Diabetic Macular Edema","enrollment":14},{"nctId":"NCT02126904","phase":"","title":"Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept","status":"UNKNOWN","sponsor":"Yokohama City University Medical Center","startDate":"2012-01","conditions":"The Injection Burden","enrollment":200},{"nctId":"NCT01640171","phase":"NA","title":"Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival","status":"COMPLETED","sponsor":"Retina Vitreous Associates of Florida","startDate":"2012-07","conditions":"Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema","enrollment":57},{"nctId":"NCT00509795","phase":"PHASE3","title":"Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2007-08","conditions":"Macular Degeneration","enrollment":1217}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1666,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Aflibercept and ranibizumab","genericName":"Aflibercept and ranibizumab","companyName":"Instituto de Olhos de Goiania","companyId":"instituto-de-olhos-de-goiania","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aflibercept and ranibizumab are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye. Used for Age-related macular degeneration (wet/neovascular), Diabetic macular edema, Retinal vein occlusion.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}